SEKISUI Diagnostics’ microbial CDMO business has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing.   Upon obtaining the necessary licenses, this expansion will enhance manufacturing capabilities for various drug types, including enzymes, proteins, antibody fragment therapies, as well as plasmids and enzymes designed for advanced gene therapy production.   BioProduction by SEKISUI serves as...